ENDRA Life Sciences Inc. (NDRA)
| Previous Close | 0.3005 |
| Open | 0.3009 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2900 - 0.3044 |
| 52 Week Range | 0.2210 - 2.7900 |
| Volume | |
| Avg. Volume | 185,806 |
| Market Cap | 3.233M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
ANN ARBOR, Mich., May 07, 2024--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer
- Business Wire
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
ANN ARBOR, Mich., May 02, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of five new patents, including three in Europe and two in China. ENDRA’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system with its novel thermoacoustic technology.
- Business Wire
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
ANN ARBOR, Mich., March 28, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
